Trastuzumab biosimilar - Biocad

Drug Profile

Trastuzumab biosimilar - Biocad

Alternative Names: BCD-022; HERtiCAD

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer

Most Recent Events

  • 07 Oct 2016 Efficacy and safety data from a phase III trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO - 2016)
  • 01 Oct 2016 Biocad completes a phase III trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Russia, India, Ukraine and Belarus (IV) (NCT01764022)
  • 20 Jan 2016 Registered for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Sri Lanka (IV) after January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top